The proposal to repurpose mebendazole as a direct replacement for vincristine in neuro-oncology addresses key pharmacological and clinical limitations of vincristine in the treatment of brain tumors.
1. Clinical Rationale: The Limitations of Vincristine
Vincristine is a standard microtubule polymerization inhibitor widely utilized in central nervous system (CNS) chemotherapy, notably as part of the PCV regimen (procarbazine, lomustine [CCNU], and vincristine) for low-grade gliomas and 1p/19q co-deleted anaplastic oligodendrogliomas. However, its clinical utility in neuro-oncology faces two critical drawbacks:
Poor Blood–Brain Barrier (BBB) Penetration: Vincristine has a high molecular weight (825 Da) and is a substrate for active efflux transporters, including P-glycoprotein (P-gp) and Mrp, severely impeding its entry into brain tumor parenchyma.
Dose-Limiting Peripheral Neuropathy: Vincristine causes significant, frequently debilitating, and sometimes permanent peripheral sensory neurotoxicity that routinely forces dose reductions or treatment discontinuation.


